BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 38671348)

  • 21. Integrated analysis of immune-related gene subtype and immune index for immunotherapy in clear cell renal cell carcinoma.
    Bai D; Chen S; Feng H; Yin A; Lu J; Ma Y; Sugiyama H
    Pathol Res Pract; 2021 Sep; 225():153557. PubMed ID: 34329838
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Landscape of immune cell infiltration in clear cell renal cell carcinoma to aid immunotherapy.
    Bai D; Feng H; Yang J; Yin A; Qian A; Sugiyama H
    Cancer Sci; 2021 Jun; 112(6):2126-2139. PubMed ID: 33735492
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular map of disulfidptosis-related genes in lung adenocarcinoma: the perspective toward immune microenvironment and prognosis.
    Zhao F; Su L; Wang X; Luan J; Zhang X; Li Y; Li S; Hu L
    Clin Epigenetics; 2024 Feb; 16(1):26. PubMed ID: 38342890
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of disulfidptosis related subtypes, characterization of tumor microenvironment infiltration, and development of DRG prognostic prediction model in RCC, in which
    Xu K; Zhang Y; Yan Z; Wang Y; Li Y; Qiu Q; Du Y; Chen Z; Liu X
    Front Immunol; 2023; 14():1205250. PubMed ID: 37426643
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Integration analysis identifies MYBL1 as a novel immunotherapy biomarker affecting the immune microenvironment in clear cell renal cell carcinoma: Evidence based on machine learning and experiments.
    Wang T; Jian W; Xue W; Meng Y; Xia Z; Li Q; Xu S; Dong Y; Mao A; Zhang C
    Front Immunol; 2022; 13():1080403. PubMed ID: 36591240
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Disulfidptosis characterizes the tumor microenvironment and predicts immunotherapy sensitivity and prognosis in bladder cancer.
    Pan G; Xie H; Xia Y
    Heliyon; 2024 Feb; 10(3):e25573. PubMed ID: 38356551
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification and verification of a novel anoikis-related gene signature with prognostic significance in clear cell renal cell carcinoma.
    He Z; Gu Y; Yang H; Fu Q; Zhao M; Xie Y; Liu Y; Du W
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11661-11678. PubMed ID: 37402968
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of a polyamine gene expression score for predicting prognosis and treatment response in clear cell renal cell carcinoma.
    Chen M; Nie Z; Huang D; Gao Y; Cao H; Zheng L; Zhang S
    Front Immunol; 2022; 13():1048204. PubMed ID: 36505496
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Construction of the metabolic reprogramming-associated gene signature for clear cell renal cell carcinoma prognosis prediction.
    Tai R; Leng J; Li W; Wu Y; Yang J
    BMC Urol; 2023 Sep; 23(1):147. PubMed ID: 37715154
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prediction of overall survival based upon a new ferroptosis-related gene signature in patients with clear cell renal cell carcinoma.
    Sun Z; Li T; Xiao C; Zou S; Zhang M; Zhang Q; Wang Z; Zhan H; Wang H
    World J Surg Oncol; 2022 Apr; 20(1):120. PubMed ID: 35422048
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A radiogenomics biomarker based on immunological heterogeneity for non-invasive prognosis of renal clear cell carcinoma.
    Gao J; Ye F; Han F; Jiang H; Zhang J
    Front Immunol; 2022; 13():956679. PubMed ID: 36177018
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of 4-genes model in papillary renal cell tumor microenvironment based on comprehensive analysis.
    Luo L; Zhou H; Su H
    BMC Cancer; 2021 May; 21(1):553. PubMed ID: 33993869
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Novel Tumor Mutation Burden Related lncRNA Signature Identified Prognosis and Tumor Immune Microenvironment Features in Clear Cell Renal Cell Carcinoma.
    Lin L; Wu XH; Zhu JM; Chen SH; Chen YH; Lin F; Xue XY; Wei Y; Xu N; Zheng QS; Sun XL
    Comb Chem High Throughput Screen; 2023; 26(8):1503-1518. PubMed ID: 36165528
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification and validation of a ferroptosis-related signature for prediction of the prognosis and tumor microenvironment in patients with chromophobe renal cell carcinoma.
    Liu S; Yao Y; Hou M; Mei J; Sun L; Zhang G
    BMC Cancer; 2023 Nov; 23(1):1079. PubMed ID: 37940859
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comprehensive insights on pivotal prognostic signature involved in clear cell renal cell carcinoma microenvironment using the ESTIMATE algorithm.
    Luo J; Xie Y; Zheng Y; Wang C; Qi F; Hu J; Xu Y
    Cancer Med; 2020 Jun; 9(12):4310-4323. PubMed ID: 32311223
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Utilizing a novel model of PANoptosis-related genes for enhanced prognosis and immune status prediction in kidney renal clear cell carcinoma.
    Jiang Z; Wang J; Dao C; Zhu M; Li Y; Liu F; Zhao Y; Li J; Yang Y; Pan Z
    Apoptosis; 2024 Jun; 29(5-6):681-692. PubMed ID: 38281281
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel risk signature based on liquid-liquid phase separation-related genes reveals prognostic and tumour microenvironmental features in clear cell renal cell carcinoma.
    Lu Q; Xi P; Xu S; Zhang Z; Gong B; Liu J; Zhu Q; Sun T; Zhu S; Chen R
    Aging (Albany NY); 2024 Mar; 16(7):6118-6134. PubMed ID: 38546385
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification and validation of an immune-related gene prognostic signature for clear cell renal carcinoma.
    Hua S; Xie Z; Zhang Y; Wu L; Shi F; Wang X; Xia S; Dong S; Jiang J
    Front Immunol; 2022; 13():869297. PubMed ID: 35936012
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel immune-related gene signature for predicting immunotherapy outcomes and survival in clear cell renal cell carcinoma.
    Gu J; Zhang X; Peng Z; Peng Z; Liao Z
    Sci Rep; 2023 Nov; 13(1):18922. PubMed ID: 37919459
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comprehensive Evaluation of the m
    Yu M; Liu X; Xu H; Shen S; Wang F; Chen D; Li G; Wang Z; Zuo Z; Zhao A
    Front Immunol; 2022; 13():818120. PubMed ID: 35784363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.